Novartis Stays Firm On India Plans After Gleevec: An Interview With India Vice Chairman Ranjit Shahani
This article was originally published in PharmAsia News
Executive Summary
Novartis has been at the center of a long patent controversy, and although it recently faced an adverse ruling, India Vice Chairman Ranjit Shahani’s optimism about the Indian market is unshaken.